ICBP Resources

Contact the ICBP team

If you have any views or comments about the  partnership, we would like to hear from you.

Email the team

The ICBP develops a range of tools, briefings and other resources. When these may be useful to the wider policy and research communities, we will make them available on this page.

These resources can be used in presentations, reports or other communications in line with the Cancer Research UK citation guide. Please contact the ICBP Programme Management team (icbp@cancer.org.uk) for more information about any of the resources on this page.

The CanStaging+  tool is available at http://canstaging.org  providing online (and offline, for limited online-service settings) access to up-to-date rules and standards in a free, intuitive, and open-source software to support better recording and increased completeness and quality of population level staging data. The tool automatically calculations T,M,N stage data based on raw information entered, and will provide a range of stage groups when data entered is limited. In addition to stage group, essential TMN, FIGO, and Dukes calculations can also be provided. Images and flowcharts are available  to assist with manual stage classification as well as education.

The ABC tool
The Awareness and Beliefs about Cancer (ABC) questionnaire is an internationally validated tool. The tool was tested in all participating countries with minor variations included to allow for differences in cultural and health systems.
 
The ABC tool is available for use by interested researchers. Please contact the ICBP Programme Management team (icbp@cancer.org.uk) for more information.
 
 
 
Survey to assess factors affecting primary care and cancer diagnosis
As part of the ICBP, researchers at the University of Oxford (United Kingdom) developed an online survey which was used to assess differences in healthcare systems, as well as how physicians respond to patients who present with symptoms within their working environment. This survey has since been carried out in New Zealand.
 
 
Further information about the survey is available from the ICBP Programme Management team (icbp@cancer.org.uk).
 
Patient, primary care and treatment specialist surveys
Using validated patient, primary care physician (PCP) and cancer treatment specialists (CTS) questionnaires, ICBP researchers will report the first robust international comparison of time intervals from first symptom(s) until start of treatment.
 
By asking newly diagnosed patients (3-6 months after diagnosis), PCPs and CTSs about the patient’s journey from symptom onset until treatment, the research team aim to provide new insights into:
  • Specific time intervals and details of a patient’s route to diagnosis and treatment.
  • The number of times a patient saw a health care professional before diagnosis.
  • The nature of any referrals and diagnostic tests carried out.
  • Associations between these factors and a range of patient outcomes (including survival and stage at diagnosis).
 
Below are samples of the survey sent to breast cancer patients, primary care practitioners and cancer treatment specialists in England. Researchers who wish to carry out this survey in their country should first contact the ICBP Programme Management team (icbp@cancer.org.uk) as these surveys exist and have been validated in other languages.
 

Reports

Our showcase reports provide an update on progress within the partnership, including findings, the impacts of our research and ongoing studies. These reports provide an overview of the partnership at certain points in time.

ICBP: Evidence for policy and practice (2016)

ICBP: Showcasing our findings and impacts (2014)

ICBP in other publications and communications

ICBP work often feeds in to the work of other organisations, including in publications, blogs and other forms of communications. Here we have provided a selection:

Building an Evidence-Based Approach to Improving Cancer Outcomes (EFPIA View 2017)

How to improve cancer survival: Exploring England’s relatively poor rates (The King’s Fund 2011)

1 and 3 year survival by stage - pancreatic - jurisdictions

3-year survival by stage and ages - pancreatic - countries 

1 and 3 - year survival by stage - pancreatic - countries 

3-year survival by distant stage - ovarian cancer - older patients - Canada

3-year survival by distant stage - ovarian cancer - older patients - UK

3-year survival by stage - NSCLC - Canadian and UK jurisdictions

3-year survival by stage - NSCLC - female

3-year survival by stage - NSCLC - male

3-year survival by stage - NSCLC & SCLC - all countries

3-year survival by stage - ovarian cancer - all countries

3-year survival by stage - ovarian cancer - Canada

3-year survival by stage - ovarian cancer - older patients - all countries

3-year survival by stage - ovarian cancer - UK

3-year survival by stage - SCLC - Canadian and UK jurisdictions

3-year survival by stage - SCLC - female

3-year survival by stage - SCLC - male

5-year survival  by stage - colon cancer

5-year survival by stage - rectal cancer

Lung overview - sex differences

Registry Lessons Learned

3-year oesophageal and gastric survival UK only

3-year oesophageal and gastric survival

1-year net survival changes

5-year net survival changes

1 year survival all jurisdictions - ovarian cancer

1 year survival all jurisdictions - colon cancer

1 year survival all jurisdictions - lung cancer

1 year survival all jurisdictions - oesophageal cancer

1 year survival all jurisdictions - pancreatic cancer

1 year survival all jurisdictions - rectal cancer

1 year survival all jurisdictions - stomach cancer

1 year survival UK only

5 year survival all jurisdictions - colon cancer

5 year survival all jurisdictions - lung cancer

5 year survival all jurisdictions - oesophageal cancer

5 year survival all jurisdictions - ovarian cancer

5 year survival all jurisdictions - pancreatic cancer

5 year survival all jurisdictions - rectal cancer

5 year survival all jurisdictions - stomach cancer

5 year survival UK only

Incidence, mortality and survival - lung cancer

Incidence, mortality and survival - colon cancer

Incidence, mortality and survival - oesophageal cancer

Incidence, mortality and survival - ovarian cancer

Incidence, mortality and survival - pancreatic cancer

Incidence, mortality and survival - rectal cancer

Incidence, mortality and survival - stomach cancer

Join us on X (previously known as Twitter)

Join the conversation and follow @CRUKHCPs for news, updates and opinion.

@CRUKHCPs

Last reviewed